Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Capital Reinvestment Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Capital Reinvestment Ratio of 0.06x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥76.07 Million) in capital expenditures (CN¥4.69 Million). See Beijing Sun Novo Pharmaceutical Research free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks Beijing Sun Novo Pharmaceutical Research Co Ltd's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. For live market cap and broader valuation context, see 688621 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | CN¥93.21 Million | CN¥42.43 Million | ▼ -52.2% |
| 2024 | 0.95x | CN¥32.02 Million | CN¥30.48 Million | ▲ +21.2% |
| 2023 | 0.79x | CN¥92.86 Million | CN¥72.96 Million | ▼ -21.4% |
| 2022 | 1.00x | CN¥103.96 Million | CN¥103.87 Million | ▲ +3.8% |
| 2021 | 0.96x | CN¥88.25 Million | CN¥84.96 Million | ▲ +124.3% |
| 2020 | 0.43x | CN¥62.99 Million | CN¥27.03 Million | ▼ -4.8% |
| 2019 | 0.45x | CN¥56.97 Million | CN¥25.67 Million | ▲ +21.1% |
| 2018 | 0.37x | CN¥44.11 Million | CN¥16.41 Million | ▼ -85.8% |
| 2017 | 2.62x | CN¥8.01 Million | CN¥20.96 Million | — |